-, Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, et al. (Moon et al., 2013) BRCA1/2 mutation patients had early-onset carboplatin hypersensitivity at a lower cumulative exposure. The site is secure. Abstracts, slide sets and webcasts from ESMO 2017 Congress are now available. Furthermore, patients with carboplatin hypersensitivity had a higher incidence of previous allergic history to other cytotoxic drugs, including gemcitabine, paclitaxel, and doxorubicin, compared to those without (12/75 vs. 30/660, P < 0.001, chi-squared test; Table 7). Please enable it to take advantage of the complete set of features! Reducing the carboplatin infusion rate and employing desensitization protocols with anti-allergy medications are especially important for patients at high risk of carboplatin hypersensitivity to detect the hypersensitivity early and avoid severe hypersensitivity without compromising the efficacy of the antineoplastic regimen. Death from anaphylaxis to cisplatin: a case report. Interactive/Pocket Guideline Interactive/Pocket Guideline Constipation in Advanced Cancer 1 2 3 Clipboard, Search History, and several other advanced features are temporarily unavailable. Access all the congress resources: webcasts, news, press, posters, videos and much more. (2009). Vaccines (Basel). Table 6. We also collected survey data from cancer nurses on safety . Login to your ESMO accountto sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Hypersensitivity to antineoplastic agents. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. The https:// ensures that you are connecting to the doi: 10.1038/bjc.2013.389, Navo, M., Kunthur, A., Badell, M. L., Coffer, L. W. desensitization; drug allergy; monoclonal antibodies in cancer; platins; taxanes. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. The annual ESMO Congress is the most prestigious and influential oncology platform in Europe and is the ideal place to learn about the latest science, network with colleagues and keep pace with today's rapid developments in cancer research. Koshiba et al. (2013). Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. An official website of the United States government. Necessary cookies enable core functionality. Multistep IgE Mast Cell Desensitization Is a Dose- and Time-Dependent Process Partially Regulated by SHIP-1. doi: 10.1016/j.ygyno.2006.10.047, Shah, A. C., Minturn, J. E., Li, Y., Belasco, J. 53, 121122. It would be worthwhile to evaluate the correlation between other HRD genes and carboplatin hypersensitivity. Multivariate analyses of clinical parameters for carboplatin-related hypersensitivity reactions. We performed tests on occupational exposure (from 10 different health care surfaces) from three types of chemotherapy (Cyclophosphamide, Gemcitabine and Fluorouracil) from three different hospitals in Sweden. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. (2003). Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches. We also found higher rates of hypersensitivity among patients with malignant ascites compared to patients without malignant ascites (P = 0.009, chi-squared test), and in patients who had experienced allergic reactions to other medications or food (e.g., paclitaxel, penicillin, aspirin) compared to patients who had not experienced previous allergic reactions (P < 0.001, chi-squared test). doi: 10.7759/cureus.24515. This patient developed hypersensitivity reactions during her 23rd cycle of carboplatin administration at a cumulative dose of approximately 14,000 mg. She experienced skin rash, tachycardia, and dyspnea 13 min after starting the infusion. These patients were provided with intravenous fluid infusion and medications, including corticosteroids, antihistamines, and oxygen application. ESMO Virtual Congress 2020 | OncologyPRO The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Methods. Nitipir C, Parosanu A, Popa AM, Cotan H, Olaru M, Iaciu C, Orlov Slavu C. Cureus. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Authors: S. Rosell, I. Blasco, L. Garca Fabregat, A. Cervantes and K. Jordan Cancer 104, 640643. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Risk Factors of Hypersensitivity to Carboplatin in Patients with This site uses cookies. Ann. 66, 265267. Merck: Driving Innovation in Cancer Care at ESMO 2017 With New Data in This site uses cookies. Gynecol. By delivering the target, Symptoms and signs of hypersensitivity reactions amendable to desensitization. We also provide recommendations for the continuation of treatment in ovarian cancer patients. Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions. Immunotherapy 6, 905912. Overall, the evidence supports that the number of carboplatin cycles and dose are the principal risk factors for carboplatin-related hypersensitivity reactions, and that caution is warranted in cases of carboplatin infusion beyond 8 cycles or 3,500 mg. All funding for this site is provided directly by ESMO. The yearly incidence of carboplatin-related hypersensitivity gradually increased from 0.88 in 2006 to 5.42% in 2013 (Table 1), in association with increased use of carboplatin. doi: 10.1016/j.ygyno.2016.09.027, Bruchim, I., Goldberg, A., Fishman, A., and Confino-Cohen, R. (2014). Evaluating whether any factors can predict carboplatin hypersensitivity, we identified a high correlation with the carboplatin cycle and cumulative dose (Pearson correlation coefficient 0.9318). See this image and copyright information in PMC. Would you like email updates of new search results? Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. In conclusion, in our present population of women with gynecological malignancies treated with platinum-based chemotherapy, 1 in 10 developed carboplatin-related hypersensitivity reactions. Note: Approved by the ESMO Guidelines Committee: July 2017, last update October 2022. . Altwerger et al. The research protocol was reviewed and approved by the institutional review board of the hospital. (2011) found that the number of treatment cycles with platinum-containing antineoplastic agents significantly correlates with the incidence of related hypersensitivity reactions. Menu icon A vertical stack of three evenly . PDF Hypersensitivity & Infusion Reaction Management - Stephenson Cancer Center All the statistical tests were two-tailed, and statistical significant level was defined as p-value < 0.05. Patients without ovarian cancer were excluded from retrospective analysis of details of hypersensitivity reactions recorded contemperaneously between April 2019 - January 2020 on excel and chemocare (CIS Oncology, Belfast, UK) by the treating practitioner. It didn't disappoint. Expert Opin Drug Saf (2003) 2(6):597607.10.1517/14740338.2.6.597 Genc et al. J. Clin. A history of drug or food allergy, the presence of malignant ascites, and the cumulative carboplatin dose are three independent predictive factors of carboplatin hypersensitivity in this survey. Oncol. Front Oncol. Hypersensitivity & Infusion Reaction Management Author: Updated 2.21.19 Subject: SCC Pharmacy Supportive and palliative care are areas of high importance in oncology and ESMO published Clinical Practice Guidelines on the management of a variety of issues: Palliative Care in the COVID-19 era, Advanced Care Planning, Anaemia and Iron Deficiency in Patients With Cancer, Anxiety and Depression,Bone Health in Cancer Patients, Cancer Cachexia in Adult Patients, Cancer Pain, Cancer-related Fatigue,Care at the End of Life, Central Venous Access in Oncology, Chemotherapy Extravasation, Constipation in Advanced Cancer, Delirium in Adult Cancer Patients,Diarrhoea in Adult Cancer Patients, Infusion Reactions to Systemic Anticancer TherapyFebrile Neutropaenia, Fertility Preservation and Post-treatment Pregnancies in Post-pubertal Cancer Patients, Management of Breathlessness in Patients with Cancer,Management of Cardiac Disease, Management of Orphan Symptoms, Neurotoxicity,Oral and Gastrointestinal Mucosal Injury, Prevention and Management of Dermatological Toxicities Related to Anticancer Agents, Prevention of Chemotherapy and Radiotherapy-Induced Nausea and Vomiting, Prognostic Evaluation in Advanced Cancer,Role of Patient-reported Outcome Measures, Toxicities from immunotherapy and Venous Thromboembolism in Cancer Patients. 2017 Jul 1;28(suppl_4):iv100-iv118. The ESMO 2017 Congress, in partnership with the European Association for Cancer Research (EACR), created an environment where cancer researchers and clinicians came together to collaborate and exchange ideas. The histological type was serous in 381 patients (51.8%) and clear cell in 148 patients (20.1%). Necessary cookies enable core functionality. 2017 Jul 1;28(suppl_4):iv119-iv142. Create your own personalised agenda and browse the complete scientific programme by day, topic, cancer type and track with the ESMO events app. | DOI: 10.1097/HS9.0000000000000695. doi: 10.1111/j.1525-1438.2005.00136.x, Koshiba, H., Hosokawa, K., Kubo, A., Miyagi, Y., Oda, T., Miyagi, Y., et al. Upon the occurrence of symptoms and signs, carboplatin infusion was immediately stopped. Met Based Drugs (2010) 2010 Available from: Markman M. Toxicities of the platinum antineoplastic agents. (2016). However, prolonged carboplatin use is associated with an increased incidence of carboplatin-related hypersensitivity reactions (Markman et al., 1999; Wang et al., 2009). (PDF) Management of cancer pain in adult patients: ESMO Clinical de Las Vecillas Snchez L, Alenazy LA, Garcia-Neuer M, Castells MC. Carboplatin and pegylated liposomal doxorubicin (Pujade-Lauraine et al., 2010) or gemcitabine (Pfisterer et al., 2006) led to superior progression-free survival of patients with platinum-sensitive recurrent ovarian cancer compared to paclitaxel and carboplatin. Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century. Successful carboplatin desensitization in patients with proven carboplatin allergy. It would be worthwhile to design a perspective trial that could randomize patients with carboplatin hypersensitivity to receive an alternative regimen without carboplatin. However, 48 (78.7%) of these patients developed repeated hypersensitivity reactions, even after pre-treatment with intravenous antihistamines, H2 blocker, and corticosteroids prior to carboplatin re-administration. 57 . Guidelines | ESMO 66, 730. Int. National Library of Medicine Prior investigations reported that a history of drug allergies correlates with the incidence of carboplatin-related hypersensitivity reactions (Libra et al., 2003; Sliesoraitis and Chikhale, 2005). 105, 8183. ESMO Clinical Practice Guideline update on the use of systemic therapy sharing sensitive information, make sure youre on a federal Accessibility Ann Oncol. The term 'hypersensitivity' should be used to describe objectively reprodu- cible symptoms or signs initiated by exposure to a dened stimu- lus at a dose tolerated by normal persons.